Article
Cyclophosphamide treatment-induced leukopenia rates in ANCA-associated vasculitis are influenced by variant CYP450 2C9 genotypes.
Pharmacogenomics - 1 Mar 2016
Schirmer Jan Henrik, Bremer Jan Phillip, Moosig Frank, Holle Julia Ulrike, Lamprecht Peter, Wieczorek Stefan, Haenisch Sierk, Cascorbi Ingolf
Abstract excerpt
AIM: Correlation of outcomes of cyclophosphamide (CP) therapy in antineutrophil cytoplasmic antibody-associated vasculitis with genotype polymorphisms in prodrug activating cytochrome P450 enzyme genes CYP2C9 and CYP2C19. PATIENTS & METHODS: One hundred and ninety six patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with CP, either as intravenous pulse or as daily oral medication,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.